1. Home
  2. PRPO vs CTXR Comparison

PRPO vs CTXR Comparison

Compare PRPO & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRPO
  • CTXR
  • Stock Information
  • Founded
  • PRPO N/A
  • CTXR 2007
  • Country
  • PRPO United States
  • CTXR United States
  • Employees
  • PRPO N/A
  • CTXR N/A
  • Industry
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • CTXR Biotechnology: Pharmaceutical Preparations
  • Sector
  • PRPO Industrials
  • CTXR Health Care
  • Exchange
  • PRPO Nasdaq
  • CTXR Nasdaq
  • Market Cap
  • PRPO 22.0M
  • CTXR 20.8M
  • IPO Year
  • PRPO N/A
  • CTXR N/A
  • Fundamental
  • Price
  • PRPO $17.59
  • CTXR $1.20
  • Analyst Decision
  • PRPO
  • CTXR Strong Buy
  • Analyst Count
  • PRPO 0
  • CTXR 3
  • Target Price
  • PRPO N/A
  • CTXR $53.00
  • AVG Volume (30 Days)
  • PRPO 16.8K
  • CTXR 453.7K
  • Earning Date
  • PRPO 11-05-2025
  • CTXR 08-12-2025
  • Dividend Yield
  • PRPO N/A
  • CTXR N/A
  • EPS Growth
  • PRPO N/A
  • CTXR N/A
  • EPS
  • PRPO N/A
  • CTXR N/A
  • Revenue
  • PRPO $21,242,000.00
  • CTXR N/A
  • Revenue This Year
  • PRPO N/A
  • CTXR N/A
  • Revenue Next Year
  • PRPO N/A
  • CTXR $851.67
  • P/E Ratio
  • PRPO N/A
  • CTXR N/A
  • Revenue Growth
  • PRPO 27.05
  • CTXR N/A
  • 52 Week Low
  • PRPO $3.90
  • CTXR $0.65
  • 52 Week High
  • PRPO $22.38
  • CTXR $15.25
  • Technical
  • Relative Strength Index (RSI)
  • PRPO 54.11
  • CTXR 44.87
  • Support Level
  • PRPO $17.00
  • CTXR $1.13
  • Resistance Level
  • PRPO $22.38
  • CTXR $1.25
  • Average True Range (ATR)
  • PRPO 1.35
  • CTXR 0.08
  • MACD
  • PRPO -0.13
  • CTXR -0.00
  • Stochastic Oscillator
  • PRPO 40.83
  • CTXR 20.85

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Share on Social Networks: